(Q24200714)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6956416&resulttype=core&format=json

13 May 2020

main subject

arterial hypertension

1 reference

Chao Liu

1

Chao

Liu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6956416&resulttype=core&format=json

13 May 2020

Junmin Chen

2

Junmin

Chen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6956416&resulttype=core&format=json

13 May 2020

Yanqiu Gao

3

Yanqiu

Gao

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6956416&resulttype=core&format=json

13 May 2020

Bao Deng

4

Bao

Deng

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6956416&resulttype=core&format=json

13 May 2020

Kunshen Liu

5

Kunshen

Liu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6956416&resulttype=core&format=json

Cochrane Database of Systematic Reviews

13 May 2020

publication date

28 February 2013

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6956416&resulttype=core&format=json

13 May 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6956416&resulttype=core&format=json

13 May 2020

page(s)

CD004434

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6956416&resulttype=core&format=json

Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.

13 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Sitaxsentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Bosentan decreases pulmonary vascular resistance and improves exercise capacity in acute hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Ambrisentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Tadalafil therapy for pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Prophylactic bosentan does not improve exercise capacity or lower pulmonary artery systolic pressure at high altitude

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

A randomised, controlled trial of bosentan in severe COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Interaction revisited: the difference between two estimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung: involvement of ETA and ETB receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Sildenafil citrate therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Guidelines for the diagnosis and treatment of pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Effects of Ro 47-0203 on endothelin-1 and sarafotoxin S6c-induced contractions of human bronchus and guinea-pig trachea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Results of European post-marketing surveillance of bosentan in pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Treatments for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Survival with first-line bosentan in patients with primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Prostacyclin for pulmonary hypertension in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Endogenously released endothelin-1 from human pulmonary artery smooth muscle promotes cellular proliferation: relevance to pathogenesis of pulmonary hypertension and vascular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Endothelin receptor antagonists for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Endothelin receptor antagonists for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Endothelin receptor antagonists for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Exercise and Respiratory Training Improve Exercise Capacity and Quality of Life in Patients With Severe Chronic Pulmonary Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Clinical and Hemodynamic Effects of Bosentan Dose Optimization in Symptomatic Heart Failure Patients with Severe Systolic Dysfunction, Associated with Secondary Pulmonary Hypertension – A Multi-Center Randomized Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Pulmonary artery pressure limits exercise capacity at high altitude

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB5

Primary pulmonary hypertension: natural history and the importance of thrombosis

21 January 2018

1 reference

12 December 2020

Endothelin receptors in cultured adult rat cardiac fibroblasts

1 reference

12 December 2020

Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis

1 reference

12 December 2020

The case for treatment of selected patients with primary pulmonary hypertension

1 reference

12 December 2020

Pulmonary vascular remodeling distal to pulmonary artery ligation is accompanied by upregulation of endothelin receptors and nitric oxide synthase

1 reference

12 December 2020

Endothelin induced collagen remodeling in experimental pulmonary hypertension

1 reference

12 December 2020

Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan

1 reference

12 December 2020

Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension

1 reference

12 December 2020

Bosentan therapy for pulmonary arterial hypertension

1 reference

12 December 2020

Chronic selective endothelin A receptor antagonism reduces serum uric acid in hypertensive chronic kidney disease

1 reference

12 December 2020

Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure

1 reference

12 December 2020

Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan

1 reference

12 December 2020

Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension

1 reference

12 December 2020

Improvement in exercise capacity with nitric oxide inhalation in patients with precapillary pulmonary hypertension

1 reference

12 December 2020

10.1002/14651858.CD004434.PUB5

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

4951188

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6956416&resulttype=core&format=json

release_ezh4x3p2y5bbtbvphq6myjmipq

13 May 2020

Fatcat ID

0 references

4951188

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6956416&resulttype=core&format=json

13 May 2020

PubMed publication ID

23450552

2 references

Consolidated OpenCitations Corpus – April 2017

4951188